Delayed treatment of symptomatic breast cancer: the experience from Kaduna, Nigeria.
Background. A cross-sectional study carried out at a teaching
hospital in Kaduna, Nigeria, to investigate the extent and reasons for
the delay between onset of symptoms and admission for treatment of
symptomatic breast cancer.
Methods. The patients had histologically proven breast cancer and had been admitted for treatment. Data were obtained from interviews and patients' clinical and referral records.
Results. One hundred and eleven consecutive breast cancer patients were interviewed from July 2003 to June 2005. Only 12 (10.8%) could be admitted for treatment within a month of onset of symptoms. Delays were significantly associated with younger patients, elementary or no Western education, and domicile outside the Kaduna metropolitan area. Patients who were referred from, or received initial treatment at, peripheral hospitals had longer delays than those who came for first consultation at the teaching hospital. The proportion of early breast cancer cases (stages I and II) decreased from 45.9% at diagnosis to 25.2% at treatment, as concerns about mastectomy and hospital treatment led a significant number of the patients to temporarily abandon hospital treatment for alternatives, only to return with advanced cancers. The predominant reasons among the 99 patients who had delays of more than a month before admission were: ignorance of the seriousness of a painless breast lump (47.5%), non-acceptance of hospital treatment (46.5%), and preference for traditional treatment (38.4%). A significant number of patients referred from peripheral hospitals had inappropriate surgeries and biopsy management which contributed to the advanced stage on admission.
Conclusion. This study shows that delayed treatment of symptomatic breast cancer at this centre in Nigeria is as much related to the quality of medical care as it is to local beliefs, ignorance of the disease, and lack of acceptance of orthodox treatment.
|Article Type:||Clinical report|
Breast cancer (Care and treatment)
Breast cancer (Demographic aspects)
|Publication:||Name: South African Journal of Surgery Publisher: South African Medical Association Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2008 South African Medical Association ISSN: 0038-2361|
|Issue:||Date: Nov, 2008 Source Volume: 46 Source Issue: 4|
|Geographic:||Geographic Scope: Nigeria Geographic Name: Kaduna, Nigeria (City); Kaduna, Nigeria (City) Geographic Code: 6NIGR Nigeria|
Breast cancer has recently overtaken carcinoma of the cervix as the
leading cause of cancer morbidity and mortality in Nigerian women. (1)
The incidence may be much lower than in developed countries, but
mortality from the disease continues to be a source of concern. The
average lifespan of a diagnosed breast cancer patient in Nigeria has
been estimated to range between 9.5 and 30 months. Orthodox medical
treatment is commenced in most of these patients at an advanced stage of
the disease (2-5) because of a higher proportion of aggressive breast
cancer variants, lack of organised screening and breast cancer control
programmes, and delays in diagnosis and treatment. (2-6)
Studies from developed countries have shown that delay between onset of symptoms and treatment of breast cancer results in disease progression and a detrimental effect on survival. (7-9) By convention, breast cancer delay has been categorised into patient delay (between onset of symptoms and first consultation with the physician) and health provider or medical delay (from first consultation to initiation of treatment). Provider delay may be diagnostic (from first consultation to confirmation of pathological diagnosis) or treatment delay (from confirmation of diagnosis to initiation of treatment).
Reports from Nigeria on breast cancer delay have tended to place more emphasis on the role of the patient in the delay, citing ignorance and misconceptions about the disease, objections to mastectomy, and faith in alternative medicine, as the common reasons for delay. (10-13) In contrast, breast cancer patients from developed nations present earlier, and a significant proportion are detected by screening mammography. Provider delay has therefore received more attention even though the prognostic implications are not quite clear. (14-20) Of interest is the study by Afzelius et al. who showed, paradoxically, worse prognosis with shorter provider delay because clinicians tend to approach the more aggressive tumours with more priority. (8) This study was conducted to investigate the factors associated with delayed treatment of symptomatic breast cancer in Kaduna, a major political and economic state capital in northern Nigeria. The study setting was Ahmadu Bello University Teaching Hospital, a major oncology centre in Nigeria.
Materials and methods
This study was of consecutive patients admitted to Ahmadu Bello University Teaching Hospital, Kaduna, from 1 July 2003 to 30 June 2005, who had histologically proven breast cancer. The policy of the unit where the study was conducted was to perform biopsies on all breast lumps during the first visit to the breast clinic, obtain results and counsel the patients within two weeks, and admit them for definitive therapy. Data were collected from the patients after admission for initial definitive therapy. Initial definitive therapy in this study strictly refers to mastectomy, neoadjuvant chemotherapy or systemic therapy.
Information obtained from the patients' clinical records included the histopathological type of breast cancer, the stage at diagnosis and at commencement of treatment, and date of admission. The Manchester staging system was used. Patients were interviewed by a surgical resident using a structured open-ended questionnaire in English, or translated to the patient. The interview commenced with limited demographic data including the patient's age, sex, religion, marital status, number of children, educational status and place of residence. Patients were asked about their initial breast symptoms, the time interval between onset of symptoms and admission, and initial steps taken by them to remedy these symptoms. Those who went to peripheral hospitals were asked about treatments and procedures carried out, biopsy results and whether or not they were counselled about breast cancer and the timing of referral. The patients were divided into two groups based on whether or not they were admitted for treatment within a month of symptoms. Delay was pegged to 1 month in this study, based on the unit's decision to ensure that biopsy processing and preparation for surgery were completed within 2 weeks. Patients who were admitted beyond 1 month of symptoms were asked why they had delayed. Information was sought about prevailing local beliefs and treatments received outside hospitals. The health care system was assumed to have contributed to the delay if, at the patient's initial consultation at the peripheral or teaching hospital, the attending physician missed the breast lump, failed to counsel the patient about the possibility of the lump being malignant, or did not refer the patient, or carried out inappropriate procedures. At the teaching hospital, other potential sources of delay that we considered included initial biopsy diagnosis of benign disease, delays in communicating the biopsy results to patients, and other logistical problems in the hospital that might have interfered with admission of patients for surgery.
Data analysis was mainly by descriptive statistics. Comparison of clinical and demographic characteristics of patients who were admitted for treatment in the first month of symptoms with those admitted after a month were subjected to chi-squared or Fisher's exact tests where appropriate, while their median ages and duration of symptoms were compared by Mann-Whitney or Kruskall-Wallis tests, where applicable. Statistical significance value was set at p=0.05.
One hundred and eleven patients were interviewed. Only 12 patients (10.8%) were admitted for treatment within 1 month of symptoms; the corresponding figure at 3 months was 21 (18.9%). The demographic characteristics of the patients are presented in Table I.
Duration of symptoms at admission for initial definitive therapy ranged from 2 weeks to 4 years, with an overall median of 9 months. Duration of symptoms was positively associated with tumour stage (p<0.05), with patients in stages I, II, III and IV linked to a median duration of symptoms of 1, 4, 8 and 12 months, respectively.
The distribution of patients by cancer stage at initial definitive treatment is reflected in Table II, showing 83 (74.7%) patients treated for advanced disease. Of these patients, 24 were initially staged in the breast clinic in stages I and II but came for admission after prolonged delays; 18 of these refused consent for mastectomy and absconded from the hospital; 4 claimed they were not aware that their biopsy results confirmed breast cancer; and 2 had admission deferred owing to industrial action by some hospital staff.
The reasons for delay in the 99 patients admitted for treatment beyond a month of symptoms are summarised in Table III. The most frequent reason (47.5%) cited was lack of awareness of the seriousness of a lump in the breast. A traditional belief that hospital treatment leads to escalation of breast cancer was initially responsible for families refusing consent for hospital admission, while those who rejected mastectomy feared for the fate of relationships with their spouses and partners or did not want their bodies to be disfigured by surgery.
None of the 40 patients referred from peripheral hospitals was admitted for definitive treatment within a month of symptoms. Their median delay (12 months) was nearly double that of the 55 patients who came directly to the teaching hospital (7 months, p<0.05). Table IV shows the frequency of provider-related delay events for patients who were admitted beyond a month of symptoms.
This study has shown that only a small fraction of breast cancer patients (10.8%) in this part of Nigeria present for treatment within a month of onset of symptoms, even though the proportion is higher than the 3-7% reported in other parts of Nigeria. (5,21) An overall median delay of 9 months, with 18.9% of patients admitted for treatment within 3 months of symptoms, is in total contrast to the situation in developed nations. For instance, Arndt et al. reported median patient and provider delays of 16 and 15 days respectively in studies from Germany, with 18% presenting to the physician beyond 3 months, (14,22) while Burgess et al. found only 19% of patients delayed more than 3 months. (17)
Demographic characteristics such as age, educational background, and place of residence relative to location of treatment centre may have small but significant influences on delays in the presentation of our patients for breast cancer treatment, consistent with reports from other parts of the world. (23-27) The majority of our adult female population are rural-based, with little or no Western education, and are disadvantaged concerning breast cancer information and proper treatment facilities. In support of this fact, 47% of those who presented late for treatment were not aware of the seriousness of a lump in the breast.
The fact that 74.7% of patients presented for treatment in stages III and IV is consistent with other reports from Nigeria, with the proportion of advanced cases ranging from 56% to 88%. (3-5,10,21,28) While this trend is similar to South African blacks, with patients in stages III and IV averaging 77%, (29) it is in total contrast to white Americans, who average 8.9% and African Americans at 13.8%, accordingly. (23,24)
Inadequate knowledge, and misconceptions about breast cancer and its treatment, even among educated Nigerians and those working within teaching hospitals, has been highlighted by Uche from Port Harcourt, (12) and Odusanya and Tayo from Lagos. (13,30) Delayed presentation caused by preferences for traditional or spiritual healing and fear of mastectomy has also been documented in other centres. (10,11,23,31) Perhaps unique to our patients is the notably high proportion of patients who believe that medical treatment of cancer leads to escalation of the disease and that hospital should not be the place for treatment. Closely linked to this belief is that consent for mastectomy must be approved by family members, regardless of the patient's needs or wishes.
Resorting to alternative medicine by patients with breast cancer is a well-documented practice. In the USA, for instance, over 28% of patients with early breast cancer are known to utilise various forms of alternative medicine while on standard medical treatment. (32) In contrast, a significant proportion of our patients go straight to traditional healers, pastors and spiritualists as a first line of treatment, as soon as a diagnosis of breast cancer is made, or on the basis of suspicion of orthodox treatment. They come back to seek standard medical treatment as a last resort, often because of pain, bleeding and offensive discharge from fungating cancers.
The reasons for resorting to alternative medicine are numerous, as can be adduced from this study. For some it offers a convenient escape from 'dreaded' mastectomy, or is an extension of denial. Affirmations such as 'I am healed in Jesus' name' or 'Breast cancer is not my option' are common with patients of Christian faith. The belief that cancer has a supernatural basis is still prevalent among our indigenous people and, to them, a cure can therefore not be found in a hospital. Other reasons may be because alternative medicine is readily accessible and affordable by the community and lauded by opinion shapers. The well-known failures and limitations of orthodox treatment of cancer also lend some credence to traditional beliefs about cancer. It should be noted that cultural beliefs which have negative effects on breast cancer presentation and mortality have also been reported among blacks in South Africa and America. (23,24,28,33)
The concept of attributing delay between initial consultation and treatment to the health care provider may not apply completely in our situation. The period of provider delay in our setting is strongly influenced by difficulties in getting consent for treatment, outright absconding from hospital after biopsy results are announced, and difficulties in financing diagnosis and treatment--as evidenced by the 18 patients who absconded from the hospital and 13% of patients who delayed because they could not initially afford the hospital fees. Burgess et al. (21) from England reported that 83% of their patients were referred during their first general practitioner visit, but this was not the case with our patients. Provider delays of 6-16%, mainly due to failure to take biopsies of lumps considered benign on mammography or false-negative biopsies, have been documented in developed countries. (15,16,19) In our patients, delays linked to the provider are most commonly associated with general practitioners who fail to refer patients promptly and proceed with unsuitable and unethical treatments such as attempting to treat a malignant breast lump by excision without sending specimens for histopathological analysis, or incising the lump as for an abscess. Such unfortunate practices take place because malpractice litigations are uncommon in this part of Nigeria, in addition to poor supervision of medical practices, little emphasis on ethics at our primary and secondary levels of health care, and lack of a well-defined community-based policy on breast cancer referral. Some private clinics capitalise on these omissions to retain patients for whom they neither have the trained personnel nor the facilities to manage, because operations bring them more profit.
In summary, late presentation for breast cancer treatment among the patients studied may be the result of a number of factors. Most of the patient population have a poor understanding of the disease and the basis of treatment. Culturally based beliefs encourage patients to seek alternatives to orthodox treatment, and many patients who seek medical treatment may simply be mismanaged at local hospitals and clinics before referral to teaching hospitals.
Data collection in this study was terminated because the teaching hospital was relocated to a permanent site in Shika-Zaria, a more rural setting 70 km away, thereby limiting the sample size. We still feel that enough lessons can be learnt from our findings to suggest a larger population-based study on delays in treatment of breast cancer, which remains an important challenge to breast cancer care in this part of Nigeria. The approach to minimising delay will require community-based campaign programmes aimed at educating the population on breast cancer and its treatment, promoting breast self-examination, enforcing referral of patients with breast symptoms to centres with facilities for diagnosis and treatment, and ensuring that these centres have laid-down policies and protocols to minimise delay.
(1.) Adebamowo CA, Ajayi OO. Breast cancer in Nigeria. West Afr J Med 2000; 19: 179-191.
(2.) Chiedozi LC. Rapidly progressing breast cancer in Nigeria. Eur J Surg Oncol 1987; 13: 505-509.
(3.) Hassan I, Onukak EE, Mabogunje OA. Breast cancer in Zaria, Nigeria. J R Coll Edinb 1992; 37: 159-161.
(4.) Anyawu SN. Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J 2000; 77: 539-543.
(5.) Anyawu SN. Breast cancer in eastern Nigeria. West Afr J Med 2000; 19: 120-125.
(6.) Otu AA, Ekanem IO, Khalil MI, Ekpo MP, Attah EB. Characterization of breast cancer sub groups in an African population. Br J Surg 1989; 76: 182-184.
(7.) Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 1999; 79: 858-864.
(8.) Afzelius P, Zedeler K, Sommer H, Mouridsen HT Blichert-Toft M. Patient and doctor's delay in primary breast cancer. Prognostic implications. Acta Oncol 1994; 33: 345-351.
(9.) Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer. Lancet 1999; 353: 1119-1126.
(10.) Ajekigbe AT. Fear of mastectomy: the most common factor associated with late presentation of carcinoma of the breast in Nigeria. Clin Oncol 1991; 3: 78-80.
(11.) Durosinmi-Etti AF. Cancer patients in Nigeria--causes of delay in diagnosis and treatment. Niger Q J Hosp Med 1985; 3: 28-30.
(12.) Uche EE. Cancer awareness among a Nigerian population. Trop Doct 1999; 29: 39-40.
(13.) Odusanya OO. Breast cancer knowledge, attitudes and practice of female school teachers in Lagos, Nigeria. Breast J 2001; 7: 171-175.
(14.) Arndt V, Sturmer T, Stegmaier C, Ziegler H, Becker A, Brennar H. Provider delay among patients with breast cancer in Germany: A population based study. J Clin Oncol 2003; 8: 1440-1446.
(15.) Goodsen WH III, Moore DH. Causes of physician delay in diagnosis of breast cancer. Arch Intern Med 2002; 162: 1343-1348.
(16.) Gorin SS, Heck JE, Bin Cheng, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 2006; 166: 2244-2252.
(17.) Burgess CC, Ramirez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer 1998; 77: 1343-1348.
(18.) Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment and clinical delays in a population based study of newly diagnosed breast carcinoma. Cancer 2004; 100: 1595-1604.
(19.) Tartter PI, Pace D, Frost M, Bernstein JL. Delay in diagnosis of breast cancer. Ann Surg 1999; 229: 91-96.
(20.) Montella M, Crispo A, D'auto G, et al. Determinant factors for diagnostic delay in operable breast cancer patents. Eur J Cancer Prev 2001; 10: 53-59.
(21.) Ihekwaba FN. Breast cancer in Nigerian women. Br J Surg 1992; 79: 771-776.
(22.) Arndt V, Sturmer T, Steigmaier C, Ziegler H, Dhom G. Brenner H. Patient delay and stage of diagnosis among breast cancers patient in Germany--a population based study. Br J Cancer 2002; 886: 1034-1040.
(23.) Lanin DR, Matthews HF, Swanson MJ. Impacting cultural attitudes in African-American women to decrease breast cancer mortality. Am J Surg 2002; 184: 418-423.
(24.) Hunter C. Epidemiology, stage at diagnosis and tumor biology of breast cancer in multiracial and multiethnic populations. Cancer 2000; 88: 1193-1202.
(25.) Millar BA, Hankey BF, Thomas TL. Impact of sociodemographic factors, hormone receptor status and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 2002; 155: 534-545.
(26.) Burgess C, Hunter MS, Ramirez AJ. A qualitative study of delay among women reporting symptoms of breast cancer. Br J Gen Pract 2001; 51: 967-971.
(27.) Meechan G, Collins J, Petrie K. Delay in seeking medical care for self-detected breast symptoms in New Zealand Women. N Z Med J 2002; 115: 257.
(28.) Hassan I. Cancer of the male breast in Zaria, Nigeria. East Afr Med J 1995; 72: 457-458.
(29.) Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J Clin Oncol 2001; 19: 125-127s.
(30.) Odusanya OO, Tayo O. Breast cancer knowledge, attitudes and practice among nurses in Lagos, Nigeria. Acta Oncol 2001; 40: 844-848.
(31.) Atoyebi OA, Atimomo CE, Adesanya AA, Beredugo BK, da Rocha-Afodu JT. An appraisal of 100 patients with breast cancer seen at Lagos University Teaching Hospital. Niger Q J Hosp Med 1997; 7: 104-108.
(32.) Burstein HJ, Gelber MS, Guadagnoli E, Weeks CJ. Use of alternative medicine by women with early stage breast cancer. N Engl J Med 1999; 340: 1737-1739.
(33.) Wright SV. An investigation into the causes of absconding black African breast cancer patients. S Afr Med J 1997; 87: 1540-1543.
A. Y. UKWENYA, M.B. B.S., F.M.C.S., F.W.A.C.S.
L. M. D. YUSUFU, M.B. B.S., F.M.C.S., F.W.A.C.S.
P. T. NMADU, M.B. B.S., F.M.C.S., F.W.A.C.S.
E. S. GARBA, M.B. B.S., F.W.A.C.S.
A. AHMED, M.B. B.S., F.W.A.C.S.
Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
TABLE I. PATIENT CHARACTERISTICS IN RELATION TO PRESENTATION DATE Admitted for treatment Within a month After a month No. of patients (%) 12 (10.8%) 99 (89.2%) p-value Median age (years) 50 43 <0.05 Marital status Currently married 11 86 Currently unmarried 1 13 Percentage currently married 91.7% 86.9% >0.05 Western education Illiterate/primary 2 57 Secondary/tertiary 10 42 Percentage secondary/tertiary 83.3% 42.4% <0.05 Location of residence Kaduna 12 61 Outside Kaduna 0 38 Percentage resident in Kaduna 100% 62% <0.05 Stage at treatment Stages I/II 11 17 Stage III/IV 1 82 Percentage stages I/II 91.7% 17.2% <0.05 TABLE II. DISTRIBUTION OF PATIENTS BY STAGE AT DEFINITIVE TREATMENT Stage No. of patients % I 10 9 II 18 16.2 III 37 33.3 IV 46 41.4 Total 111 99.9 TABLE III. PATIENTS' REASONS FOR DELAY (N=99) Reasons for delay No. of patients % Patient not aware of seriousness of a lump in the breast 47 47.5 Went for alternative (traditional/spiritual) treatment 38 38.4 Family refused hospital treatment 25 25.3 Did not want mastectomy as treatment 21 21.2 Could not initially afford hospital treatment 13 13.1 Note: Many patients gave several reasons. TABLE IV EVENTS ASSOCIATED WITH PROVIDER DELAY IN 99 PATIENTS Event No. of patients % Failure to refer patient at first consultation 40 40.4 Attempted treatment by lumpectomy with recurrence 15 15.1 Lump not sent for histopathological examination 14 14.1 Patient not counselled about seriousness of breast lump 13 13.1 Breast lump mistakenly incised as an abscess 10 10.1 Breast lump not felt at initial examination 7 7 Biopsy result not immediately communicated to patient 4 4 Initial biopsy diagnosis of benign disease 3 3 Note: Some patients had several delay events.
|Gale Copyright:||Copyright 2008 Gale, Cengage Learning. All rights reserved.|